Business
NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
EL SEGUNDO, Calif.--(BUSINESS WIRE)-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of
About this update from Immunitybio, Inc.
[{"type":"text","content":" EL SEGUNDO, Calif.--(BUSINESS WIRE)--\nNantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET.\n\n\nA live audio webcast of the conference presentation will be available on the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days.\n\n\nDr. Soon-Shiong will present a clinical pipeline update with registrational strategies for NantKwest’s off-the-shelf natural killer cell-based therapeutics in combination with ImmunityBio’s N-803 Interleukin 15 (IL-15) ‘superagonist’ cytokine. He will also provide an update on the companies’ COVID-19 therapeutic and vaccine candidates.\n\n\nAbout NantKwest\n\n\nNantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally-induced infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by delivering living drugs-in-a-bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit www.nantkwest.com\n\n\nhaNK is a registered trademark of NantKwest, Inc.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that NantKwest will be successful in improving the treatment of cancer. Risks and uncertai...